WESTERN NEW YORK – A medical device to treat childhood Attention Deficit Hyperactivity Disorder (ADAD) has been approved by the U.S. Food and Drug Administration (FDA).
It’s the first medical device of its kind. The Monarch External Trigeminal Nerve Stimulation System was given the ‘okay’ by the FDA on Friday.
It’s designated for children ages seven to 12 who are not currently on medication for the disorder; and is designed to be worn while a child is sleeping.
A small adhesive patch is placed on the child’s forehead and the pocket-sized delivers a low-level electrical pulse to the parts of the brain responsible for ADAD symptoms.
The device has also been investigated as a possible treatment for traumatic brain injury in veterans.